AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$DVA

Rodriguez Javier sold $14.5M of DVA

Rodriguez Javier (Chief Executive Officer) sold 69,407 shares of DAVITA INC. (DVA) at an average of $209.38 ($209.28–$209.50, $14.53M total) across 2 trades over 2026-06-15 to 2026-06-16.

Original reporting
SEC EDGAR · Rodriguez Javier
Published Jun 17, 2026, 10:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DVA
Bearish
medium confidence
Mentioned
$DVA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVABearishLow
01

Why it matters

The only new information is the disclosed open-market sale size and pricing; there is no accompanying company performance or guidance update in the text.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing without additional fundamental catalysts.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says none), nor does it provide context on total compensation, prior sale cadence, or remaining holdings beyond the post-trade figure.

Relevance 7/10Novelty 6/10Timing: Filed June 17; sale executed June 15–16

Background

SEC Form 4 reports an insider transaction by DaVita’s CEO, Rodriguez Javier, including trade dates, share count, and price range.

Company-level read

Ticker impact

$DVABearishMedium confidence
Context

DaVita CEO Rodriguez Javier sold 69,407 shares in open-market transactions at about $209.28–$209.50 per share, per Form 4 filed June 17.

Expected impact

Likely limited near-term impact; any effect should fade unless follow-on selling or other news emerges.

Evidence & confidence

The disclosure is a routine Form 4 insider sale (no 10b5-1 plan stated) with a defined transaction window, but the article provides no earnings, guidance, or regulatory/operational change.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide datapoint.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; the filing does not prove negative expectations about the business.

Key entities

  • issuer
    DAVITA INC.

    Subject of the Form 4 insider transaction; CEO sold shares in June 15–16 trades.

  • insider
    Rodriguez Javier

    DaVita CEO and director who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DVA insider trading history →

Related articles

$DVAMed

Washington state accuses largest dialysis providers DaVita, Fresenius of suppressing competition

Washington state sued DaVita and Fresenius Medical Care, alleging they suppress competition by requiring nephrologists to sign noncompete agreements, reducing patient treatment options. The state seeks to void these agreements and impose fines. DaVita denies wrongdoing; Fresenius did not comment. The FTC is also investigating. DaVita operates 51 centers in Washington, Fresenius 29, with some areas having only one provider.

finance.yahoo.com
$DVAMedAI 8/10

DaVita (DVA) Q3 2026 Earnings Call Transcript

DaVita (DVA) reported Q3 2026 adjusted operating income of $561M and EPS of $3.82. The company highlighted clinical advancements in fluid management and expanded HD dialyzers, expecting a national rollout by November. DaVita raised its Integrated Kidney Care (IKC) guidance to $65M for 2026, citing improved savings rates and partnerships. Full-year 2026 adjusted operating income is projected to be $2.175B-$2.25B, with EPS between $14.30-$15.20.

finance.yahoo.com
$DVAHighAI 9/10

What DaVita (DVA) Said on Its Q3 Earnings Call

DaVita (DVA) reported Q3 earnings, highlighting a 20% year-over-year increase in technology spending and a national rollout of expanded hemodialysis dialyzers. The company expects technology investment growth to decelerate but not decline in 2027. DaVita raised its outlook for Integrated Kidney Care, projecting at least $65 million in adjusted operating income for 2026.

finance.yahoo.com
$DVAHighAI 8/10

DaVita Inc (DVA) (Q3 2026) Earnings Call Highlights: IKC Guidance Raised, Expanded HD

DaVita Inc (DVA) narrowed its 2026 adjusted operating income and EPS guidance due to higher US dialysis costs. Revenue per treatment grew 1.1% YoY, while patient care costs rose 2.4%. The new ESRD rule's 3.5% rate increase is expected to have a net impact of 1.5% to 2% for 2027. CEO Javier Rodriguez highlighted growth plans for the IKC business and the company's stance on the HHS Kidney Care National Plan.

finance.yahoo.com
$DVAHighAI 9/10

DaVita’s (NYSE:DVA) Q3 2026: beats on revenue but stock drops

DaVita (DVA) reported Q3 2026 revenue of $3.58B, beating estimates by 1.7% YoY. Adjusted EPS of $3.82 exceeded expectations by 6.9%. Management raised full-year EPS guidance to $14.75. Operating margin remained steady at 14%, but free cash flow margin declined to 7.7% from 19.7% YoY. Sales volumes increased 1.2% YoY, reversing a prior decline.

finance.yahoo.com